Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Xenetic Biosciences, Inc. XBIO

Healthcare  —  Biotechnology
2.37 (0.10) (4.05%) as of 25 Sep
Market cap
$5.8M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Xenetic Biosciences, Inc. (XBIO) Business Profile

Updated before January 2025

Company Overview

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing innovative therapies to address unmet medical needs. Founded in 1997, the company is headquartered in Framingham, Massachusetts, USA. Over the years, Xenetic has evolved from a research-focused entity into a clinical-stage biopharmaceutical company with a robust pipeline of proprietary technologies and therapies. The company is led by a team of seasoned executives, including Jeffrey Eisenberg, who serves as the Chief Executive Officer, and Curtis Lockshin, Ph.D., the Chief Scientific Officer. Their leadership has been instrumental in driving the company’s strategic initiatives and fostering partnerships with global pharmaceutical companies.

Core Business Segments

Xenetic Biosciences operates primarily in the field of biopharmaceuticals, with a focus on developing therapies for oncology and other critical diseases. The company’s core business segments include:

1. Oncology Therapeutics

Xenetic’s primary focus is on advancing therapies for cancer treatment. The company’s lead product candidate, XCART™, is a personalized T-cell therapy platform designed to target patient-specific tumor neoantigens. XCART™ aims to revolutionize the treatment of B-cell malignancies by offering a highly targeted and effective approach.

2. PolyXen® Technology

PolyXen® is Xenetic’s proprietary drug delivery platform that utilizes polysialylation technology to improve the pharmacokinetics and pharmacodynamics of biologic drugs. This technology enhances the efficacy and safety profile of therapeutic proteins and peptides, making it a valuable asset for drug development.

3. Partnerships and Licensing

Xenetic collaborates with global pharmaceutical companies to leverage its proprietary technologies. The company has established partnerships with entities such as Takeda Pharmaceuticals and Serum Institute of India, which provide additional revenue streams through licensing agreements and royalties.

Business Model

Xenetic Biosciences operates on a hybrid business model that combines in-house drug development with strategic partnerships. The company generates revenue through:

  • Product Development: Advancing its proprietary therapies, such as XCART™, through clinical trials and eventual commercialization.
  • Licensing Agreements: Licensing its PolyXen® technology to pharmaceutical companies for use in their drug development programs.
  • Royalties: Earning royalties from partnered products that utilize Xenetic’s technologies.

This diversified approach allows Xenetic to mitigate risks associated with drug development while maximizing its revenue potential.

Strategic Direction

Xenetic Biosciences is committed to advancing its pipeline of innovative therapies and expanding its technological capabilities. Key strategic initiatives include:

  • Advancing XCART™: The company is focused on progressing XCART™ through preclinical and clinical development to establish it as a leading therapy for B-cell malignancies.
  • Expanding PolyXen® Applications: Xenetic aims to broaden the use of its PolyXen® technology across various therapeutic areas, including hematology and immunology.
  • Sustainability Goals: While not explicitly stated, the company is likely to adopt sustainable practices in its operations and product development to align with industry trends.
  • Exploring New Markets: Xenetic is actively seeking opportunities to expand its presence in emerging markets and diversify its product portfolio.

Competitive Landscape

Xenetic Biosciences operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • CAR-T Therapy Developers: Companies like Kite Pharma (a Gilead company) and Novartis are major players in the CAR-T therapy space, competing directly with Xenetic’s XCART™ platform.
  • Drug Delivery Technology Providers: Competitors in the drug delivery segment include Halozyme Therapeutics and Ascendis Pharma, which offer alternative technologies to PolyXen®.
  • Biopharmaceutical Companies: Broader competition comes from established biopharma companies like Amgen, Biogen, and Regeneron, which have extensive pipelines and resources.

Risk Factors

Xenetic Biosciences faces several risks that could impact its operations and financial performance:

  • Market Dependence: The company’s success is heavily reliant on the development and commercialization of its lead product candidates.
  • Regulatory Challenges: Navigating the complex regulatory landscape for drug approval poses significant risks.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers could lead to delays or interruptions in production.
  • Competition: Intense competition from larger, well-funded companies could limit Xenetic’s market share.
  • Financial Constraints: As a clinical-stage company, Xenetic may face challenges in securing sufficient funding to advance its pipeline.

Recent Developments

Xenetic Biosciences has made significant strides in recent years, including:

  • XCART™ Progress: The company has reported promising preclinical data for XCART™ and is preparing for clinical trials.
  • Partnership Expansion: Xenetic has strengthened its collaboration with existing partners and is exploring new licensing opportunities.
  • Corporate Strategy: The company has streamlined its operations to focus on its core competencies, enhancing efficiency and reducing costs.
  • Global Developments: The COVID-19 pandemic highlighted the importance of innovative therapies, potentially increasing demand for Xenetic’s technologies.

Investment Considerations

Investors considering Xenetic Biosciences should weigh the following factors:

Strengths

  • Innovative Pipeline: A strong focus on personalized medicine and drug delivery technologies.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies provide financial stability and market validation.
  • Market Potential: Significant growth opportunities in oncology and drug delivery markets.

Risks

  • Early-Stage Company: Limited revenue generation and dependence on external funding.
  • Regulatory Hurdles: Lengthy and uncertain approval processes for new therapies.
  • Competitive Pressure: Intense competition from established players in the biopharmaceutical industry.

Conclusion

Xenetic Biosciences, Inc. is a promising player in the biopharmaceutical industry, with a focus on innovative therapies and drug delivery technologies. While the company faces challenges typical of early-stage biotechs, its strong pipeline, strategic partnerships, and market potential position it for long-term growth. Investors should carefully consider the associated risks and rewards when evaluating Xenetic as an investment opportunity.